A REVIEW OF IMB-808

ACE inhibitors stop angiotensin I from changing to angiotensin II, ARBS avoid the binding of angiotensin II on to blood vessel receptorsIn the Ph2b trial, ibezapolstat-treated clients showed decrease concentrations of fecal Most important bile acids, and higher effective ratio of secondary to Principal bile acids than vancomycin-handled individuals